Objective: To review the treatment of methicillin-resistant Staphylococcus aureus (MRSA)–associated acute pulmonary exacerbations (APEs) in cystic fibrosis (CF). Data Sources: A search of PubMed, MEDLINE, Cochrane Library and Clinicaltrials.gov databases through November 2014 was conducted using the search terms Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, pulmonary exacerbations, and cystic fibrosis. Study Selection and Data Extraction: All English-language research articles, case reports, and case series were evaluated. A total of 185 articles were identified related to MRSA and CF; 30 articles that studied treatments of MRSA APE in CF were included. Data Synthesis: The persistent presence of MRSA in the respiratory tract of patients with CF has been associated with higher morbidity and an increased risk of death. Limited clinical data exist supporting the efficacy of any specific antimicrobial currently available for the treatment of APE secondary to MRSA. Conclusions: Data extrapolated from other populations suggest that vancomycin and linezolid are appropriate first-line treatment options for the treatment of APE secondary to MRSA. Second-line options include doxycycline or minocycline and trimethoprim/sulfamethoxazole, each of which may be useful in patients coinfected with other respiratory pathogens, for which they may provide overlapping coverage. Ceftaroline and ceftobiprole are newer antibiotics that appear to have a potential role in the treatment of APE in CF, but the latter is not currently available to the US market. Although potentially useful, clindamycin is limited by high rates of resistance, telavancin is limited by its toxicity profile, and tigecycline is limited by a lack of demonstrated efficacy for infections that are similar to that seen in the CF population. Studies investigating the clinical utility of the above-cited antibiotics for APE in CF secondary to MRSA are desperately needed to broaden the treatment armamentarium for this medical condition.
BhattJM. Treatment of pulmonary exacerbations in cystic fibrosis. Eur Respir Rev. 2013;22:205-216. doi:10.1183/09059180.00006512.
2.
FlumePAMogayzelPJJrRobinsonKA. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009;180:802-808. doi:10.1164/rccm.200812-1845PP.
3.
DoringGFlumePHeijermanH. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros. 2012;11:461-479. doi:10.1016/j.jcf.2012.10.004.
4.
ParkinsMDElbornJS. Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management. J Antimicrob Chemother. 2010;65:1853-1861. doi:10.1093/jac/dkq245.
5.
DasenbrookECCheckleyWMerloCAKonstanMWLechtzinNBoyleMP. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA. 2010;303:2386-2392. doi:10.1001/jama.2010.791.
KahlBC. Impact of Staphylococcus aureus on the pathogenesis of chronic cystic fibrosis lung disease. Int J Med Microbiol. 2010;300:514-519. doi:10.1016/j.ijmm.2010.08.002.
8.
DasenbrookECMerloCADiener-WestMLechtzinNBoyleMP. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med. 2008;178:814-821. doi:10.1164/rccm.200802-327OC.
9.
RenCLMorganWJKonstanMW. Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function. Pediatr Pulmonol. 2007;42:513-518. doi:10.1002/ppul.20604.
10.
VanderhelstEDe MeirleirLVerbanckSPierardDVinckenWMalfrootA. Prevalence and impact on FEV(1) decline of chronic methicillin-resistant Staphylococcus aureus (MRSA) colonization in patients with cystic fibrosis: a single-center, case control study of 165 patients. J Cyst Fibros. 2012;11:2-7. doi:10.1016/j.jcf.2011.08.006.
11.
CoxDWKellyCRushRO’SullivanNCannyGLinnaneB. The impact of MRSA infection in the airways of children with cystic fibrosis; a case-control study. Ir Med J. 2011;104:305-308.
12.
GangellCGardSDouglasT. Inflammatory responses to individual microorganisms in the lungs of children with cystic fibrosis. Clin Infect Dis. 2011;53:425-432. doi:10.1093/cid/cir399.
13.
SagelSDGibsonRLEmersonJ. Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr. 2009;154:183-188. doi:10.1016/j.jpeds.2008.08.001.
14.
WolterDJEmersonJCMcNamaraS. Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis. Clin Infect Dis. 2013;57:384-391. doi:10.1093/cid/cit270.
15.
FlumePAO’SullivanBPRobinsonKA. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007;176:957-969. doi:10.1164/rccm.200705-664OC.
16.
SzaffMHoibyNFlensborgEW. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand. 1983;72:651-657.
17.
ZobellJTYoungDCHatchM. Utilization of antibiotics for methicillin-resistant Staphylococcus aureus infection in cystic fibrosis patients. Pediatr Pulmonol. 2013;48:311.
18.
StoneASaimanL. Update on the epidemiology and management of Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus, in patients with cystic fibrosis. Curr Opin Pulm Med. 2007;13:515-521. doi:10.1097/MCP.0b013e3282efbbac.
19.
Cakir AktasNErturanZKaratunaOKarahasan YagciA. Panton-Valentine leukocidin and biofilm production of Staphylococcus aureus isolated from respiratory tract. J Infect Dev Ctries. 2013;7:888-891. doi:10.3855/jidc.4135.
20.
BesierSSmacznyCvon MallinckrodtC. Prevalence and clinical significance of Staphylococcus aureus small-colony variants in cystic fibrosis lung disease. J Clin Microbiol. 2007;45:168-172. doi:10.1128/JCM.01510-06.
21.
StoneAQuittellLZhouJ. Staphylococcus aureus nasal colonization among pediatric cystic fibrosis patients and their household contacts. Pediatr Infect Dis J. 2009;28:895-899.
22.
ElizurAOrschelnRCFerkolTW. Panton-Valentine Leukocidin-positive methicillin-resistant Staphylococcus aureus lung infection in patients with cystic fibrosis. Chest. 2007;131:1718-1725. doi:10.1378/chest.06-2756.
23.
NadesalingamKConwaySPDentonM. Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis. J Cyst Fibros. 2005;4:49-52. doi:10.1016/j.jcf.2004.09.002.
24.
ChmielJFAksamitTRChotirmallSH. Antibiotic management of lung infections in cystic fibrosis: I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections. Ann Am Thorac Soc. 2014;11:1120-1129. doi:10.1513/AnnalsATS.201402-050AS.
25.
LamerCde BecoVSolerP. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother. 1993;37:281-286.
26.
GossCHMuhlebachMS. Review: Staphylococcus aureus and MRSA in cystic fibrosis. J Cyst Fibros. 2011;10:298-306. doi:10.1016/j.jcf.2011.06.002.
27.
van HalSJLodiseTPPatersonDL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012;54:755-771. doi:10.1093/cid/cir935.
28.
CafisoVBertuccioTSpinaD. Methicillin resistance and vancomycin heteroresistance in Staphylococcus aureus in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis. 2010;29:1277-1285. doi:10.1007/s10096-010-1000-5.
29.
FilleronAChironRReverdyME. Staphylococcus aureus with decreased susceptibility to glycopeptides in cystic fibrosis patients. J Cyst Fibros. 2011;10:377-382. doi:10.1016/j.jcf.2011.05.001.
30.
RybakMJLomaestroBMRotschaferJC. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2009;29:1275-1279.
31.
PatelNPaiMPRodvoldKALomaestroBDrusanoGLLodiseTP. Vancomycin: we can’t get there from here. Clin Infect Dis. 2011;52:969-974. doi:10.1093/cid/cir078.
32.
PleasantsRAMichaletsELWilliamsDMSamuelsonWMRehmJRKnowlesMR. Pharmacokinetics of vancomycin in adult cystic fibrosis patients. Antimicrob Agents Chemother. 1996;40:186-190.
33.
StockmannCSherwinCMZobellJT. Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis. Pharmacotherapy. 2013;33:1288-1296. doi:10.1002/phar.1320.
34.
FungL. Continuous infusion vancomycin for treatment of methicillin-resistant Staphylococcus aureus in cystic fibrosis patients. Ann Pharmacother. 2012;46:e26. doi:10.1345/aph.1R272.
35.
LiuCBayerACosgroveSE. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52:285-292. doi:10.1093/cid/cir034.
36.
JungYJKohYHongSB. Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. Crit Care Med. 2010;38:175-180.
37.
TremblaySLauTTEnsomMH. Addition of rifampin to vancomycin for methicillin-resistant Staphylococcus aureus infections: what is the evidence?Ann Pharmacother. 2013;47:1045-1054. doi:10.1345/aph.1R726.
SinclairEAYenokyanGMcMunnAFadrowskiJJMilstoneAMLeeCK. Factors associated with acute kidney injury in children receiving vancomycin. Ann Pharmacother. 2014;48:1555-1562. doi:10.1177/1060028014549185.
40.
BoselliEBreilhDRimmeleT. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med. 2005;33:1529-1533.
41.
ConteJEJrGoldenJAKippsJZurlindenE. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother. 2002;46:1475-1480.
42.
GalesACSaderHSAndradeSSLutzLMachadoABarthAL. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int J Antimicrob Agents. 2006;27:300-302. doi:10.1016/j.ijantimicag.2005.11.008.
43.
HillRLKearnsAMNashJ. Linezolid-resistant ST36 methicillin-resistant Staphylococcus aureus associated with prolonged linezolid treatment in two paediatric cystic fibrosis patients. J Antimicrob Chemother. 2010;65:442-445. doi:10.1093/jac/dkp494.
44.
RomanFRoldanCTrincadoPBallesterosCCarazoCVindelA. Detection of linezolid-resistant Staphylococcus aureus with 23S rRNA and novel L4 riboprotein mutations in a cystic fibrosis patient in Spain. Antimicrob Agents Chemother. 2013;57:2428-2429. doi:10.1128/AAC.00208-13.
45.
TaziAChapronJTouakG. Rapid emergence of resistance to linezolid and mutator phenotypes in Staphylococcus aureus isolates from an adult cystic fibrosis patient. Antimicrob Agents Chemother. 2013;57:5186-5188. doi:10.1128/AAC.01392-13.
46.
EndimianiABlackfordMDasenbrookEC. Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio. Antimicrob Agents Chemother. 2011;55:1684-1692. doi:10.1128/AAC.01308-10.
47.
SaralayaDPeckhamDGHulmeB. Serum and sputum concentrations following the oral administration of linezolid in adult patients with cystic fibrosis. J Antimicrob Chemother. 2004;53:325-328. doi:10.1093/jac/dkh072.
48.
BossoJAFlumePAGraySL. Linezolid pharmacokinetics in adult patients with cystic fibrosis. Antimicrob Agents Chemother. 2004;48:281-284.
49.
AndesDvan OgtropMLPengJCraigWA. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother. 2002;46:3484-3489.
50.
RaynerCRForrestAMeagherAKBirminghamMCSchentagJJ. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet. 2003;42:1411-1423. doi:10.2165/00003088-200342150-00007.
51.
KeelRASchaeftleinAKloftC. Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis. Antimicrob Agents Chemother. 2011;55:3393-3398. doi:10.1128/AAC.01797-10.
52.
BeringerPNguyenMHoemN. Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings. Antimicrob Agents Chemother. 2005;49:3676-3681. doi:10.1128/AAC.49.9.3676-3681.2005.
53.
ChiappiniEContiCGalliLde MartinoM. Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. Clin Ther. 2010;32:66-88. doi:10.1016/j.clinthera.2010.01.019.
54.
SantosRPPrestidgeCBBrownME. Pharmacokinetics and pharmacodynamics of linezolid in children with cystic fibrosis. Pediatr Pulmonol. 2009;44:148-154. doi:10.1002/ppul.20966.
55.
FerrinMZuckermanJBMeagherABlumbergEA. Successful treatment of methicillin-resistant Staphylococcus aureus pulmonary infection with linezolid in a patient with cystic fibrosis. Pediatr Pulmonol. 2002;33:221-223.
56.
SerisierDJJonesGCarrollM. Eradication of pulmonary methicillin-resistant Staphylococcus aureus (MRSA) in cystic fibrosis with linezolid. J Cyst Fibros. 2004;3:61. doi:10.1016/j.jcf.2003.12.010.
57.
RubinsteinECammarataSOliphantTWunderinkR; Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis. 2001;32:402-412. doi:10.1086/318486.
58.
WunderinkRGCammarataSKOliphantTHKollefMH; Linezolid Nosocomial Pneumonia Study Group. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther. 2003;25:980-992.
59.
Zyvox (Linezolid) [product information].New York, NY: Pfizer; 2014.
60.
HuangVGortneyJS. Risk of serotonin syndrome with concomitant administration of linezolid and serotonin agonists. Pharmacotherapy. 2006;26:1784-1793. doi:10.1592/phco.26.12.1784.
61.
NambiarSRellosaNWasselRTBorders-HemphillVBradleyJS. Linezolid-associated peripheral and optic neuropathy in children. Pediatrics. 2011;127:e1528-e1532. doi:10.1542/peds.2010-2125.
62.
BeringerPMOwensHNguyenABenitezDRaoAD’ArgenioDZ. Pharmacokinetics of doxycycline in adults with cystic fibrosis. Antimicrob Agents Chemother. 2012;56:70-74. doi:10.1128/AAC.05710-11.
63.
ChampionEAMillerMBPopowitchEB. Antimicrobial susceptibility and molecular typing of MRSA in cystic fibrosis. Pediatr Pulmonol. 2013;49:230-237. doi:10.1002/ppul.22815.
64.
CocchiPCarianiLFavariF. Molecular epidemiology of meticillin-resistant Staphylococcus aureus in Italian cystic fibrosis patients: a national overview. J Cyst Fibros. 2011;10:407-411. doi:10.1016/j.jcf.2011.06.005.
65.
PattersonPR. Minocycline in the antibiotic regimen of cystic fibrosis patients: weight gain and clinical improvement. Clin Pediatr. 1977;16:60-63.
66.
American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388-416. doi:10.1164/rccm.200405-644ST.
67.
SanchezARRogersRSIIISheridanPJ. Tetracycline and other tetracycline-derivative staining of the teeth and oral cavity. Int J Dermatol. 2004;43:709-715. doi:10.1111/j.1365-4632.2004.02108.
68.
ReedMDSternRCBertinoJSJrMyersCMYamashitaTSBlumerJL. Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis. J Pediatr. 1984;104:303-307.
69.
CitronDMTyrrellKLMerriamCVGoldsteinEJ. In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria. Antimicrob Agents Chemother. 2010;54:1627-1632. doi:10.1128/AAC.01788-09.
70.
GeYBiekDTalbotGHSahmDF. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother. 2008;52:3398-3407. doi:10.1128/AAC.00149-08.
71.
PolenakovikHMPleimanCM. Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature. Int J Antimicrob Agents. 2013;42:450-455. doi:10.1016/j.ijantimicag.2013.07.005.
72.
SaravolatzLPawlakJJohnsonL. In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2010;54:3027-3030. doi:10.1128/AAC.01516-09.
73.
FileTMJrLowDEEckburgPB. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis. 2010;51:1395-1405. doi:10.1086/657313.
74.
VidaillacCLeonardSNRybakMJ. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model. Antimicrob Agents Chemother. 2009;53:4712-4717. doi:10.1128/AAC.00636-09.
75.
MolloyLSnyderAHSrivastavaRRybakMJMcGrathE. Ceftaroline fosamil for methicillin-resistant Staphylococcus aureus pulmonary exacerbation in a pediatric cystic fibrosis patient. J Pediatr Pharmacol Ther. 2014;19:135-140. doi:10.5863/1551-6776-19.2.135.
76.
ZhanelGGLamASchweizerF. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin. Am J Clin Dermatol. 2008;9:245-254.
77.
LaohavaleesonSTessierPRNicolauDP. Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains. Antimicrob Agents Chemother. 2008;52:2389-2394. doi:10.1128/AAC.01422-07.
78.
AwadSSRodriguezAHChuangYC. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia [published online April9, 2014]. Clin Infect Dis. doi:10.1093/cid/ciu219.
HandWLCorwinRWSteinbergTHGrossmanGD. Uptake of antibiotics by human alveolar macrophages. Am Rev Respir Dis. 1984;129:933-937.
81.
ShaperaRMWarwickWJMatsenJM. Clindamycin therapy of staphylococcal pulmonary infections in patients with cystic fibrosis. J Pediatr. 1981;99:647-650.
82.
MandellLAWunderinkRGAnzuetoA. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(suppl 2):S27-S72. doi:10.1086/511159.
83.
BradleyJSByingtonCLShahSS. Executive summary: the management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011;53:617-630. doi:10.1093/cid/cir625.
84.
MooreZSJerrisRCHilinskiJA. High prevalence of inducible clindamycin resistance among Staphylococcus aureus isolates from patients with cystic fibrosis. J Cyst Fibros. 2008;7:206-269. doi:10.1016/j.jcf.2007.07.010.
85.
GlikmanDSiegelJDDavidMZ. Complex molecular epidemiology of methicillin-resistant Staphylococcus aureus isolates from children with cystic fibrosis in the era of epidemic community-associated methicillin-resistant S aureus. Chest. 2008;133:1381-1387. doi:10.1378/chest.07-2437.
86.
GuskeyMTTsujiBT. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin. Pharmacotherapy. 2010;30:80-94. doi:10.1592/phco.30.1.80.
87.
LodiseTPJrGotfriedMBarriereSDrusanoGL. Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother. 2008;52:2300-2304. doi:10.1128/AAC.01110-07.
88.
GanderSKinnairdAFinchR. Telavancin: in vitro activity against staphylococci in a biofilm model. J Antimicrob Chemother. 2005;56:337-343. doi:10.1093/jac/dki198.
RubinsteinELalaniTCoreyGR. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis. 2011;52:31-40. doi:10.1093/cid/ciq031
91.
PolyzosKAMavrosMNVardakasKZMakrisMCRafailidisPIFalagasME. Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis. PLoS One. 2012;7:e41870. doi:10.1371/journal.pone.0041870.
92.
FlorescuIBeuranMDimovR. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother. 2008;62(suppl 1):i17-i28. doi:10.1093/jac/dkn250.
93.
Norskov-LauritsenNMarchandinHDowzickyMJ. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007). Int J Antimicrob Agents. 2009;34:121-130. doi:10.1016/j.ijantimicag.2009.02.003.
94.
SloverCMRodvoldKADanzigerLH. Tigecycline: a novel broad-spectrum antimicrobial. Ann Pharmacother. 2007;41:965-972. doi:10.1345/aph.1H543.
95.
ConteJEJrGoldenJAKellyMGZurlindenE. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents. 2005;25:523-529. doi:10.1016/j.ijantimicag.2005.02.013.
BurkhardtORauchKKaeverVHademJKielsteinJTWelteT. Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int J Antimicrob Agents. 2009;34:101-102. doi:10.1016/j.ijantimicag.2009.01.015.
98.
CaiYWangRLiangBBaiNLiuY. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother. 2011;55:1162-1172. doi:10.1128/AAC.01402-10.
99.
McGovernPCWibleMEl-TahtawyABiswasPMeyerRD. All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials. Int J Antimicrob Agents. 2013;41:463-467. doi:10.1016/j.ijantimicag.2013.01.020.
100.
PrasadPSunJDannerRLNatansonC. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis. 2012;54:1699-1709. doi:10.1093/cid/cis270.
101.
TasinaEHaidichABKokkaliSArvanitidouM. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis. 2011;11:834-844. doi:10.1016/S1473-3099(11)70177-3.
102.
YahavDLadorAPaulMLeiboviciL. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother. 2011;66:1963-1971. doi:10.1093/jac/dkr242.
103.
US Food and Drug Administration. FDA Drug Safety Communication: increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm. Accessed October 1, 2014.
104.
US Food and Drug Administration. FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning. http://www.fda.gov/drugs/drugsafety/ucm369580.htm. Accessed October 1, 2014.
105.
WallaceRJJrDukartGBrown-ElliottBAGriffithDEScerpellaEGMarshallB. Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections. J Antimicrob Chemother. 2014;69:1945-1953. doi:10.1093/jac/dku062.
